Donohue syndrome and use of continuous subcutaneous IGF1 pump therapy
Problems of Endocrinology · 22.06.2022 · 68 (5) · 79-86
DOI: 10.14341/probl13121 ↗Kurz gefasst
Fallbericht in der Zeitschrift Problems of Endocrinology, online erschienen am 22.06.2022. Verfasst von M A Melikyan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Research Centre. Hauptthemen laut MEDLINE: Donohue Syndrome, Insulin Resistance. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Donohue syndrome (DS), also called Leprechaunism, is the most severe form of insulin resistance associated with biallelic mutations in INSR gene (OMIM: 147670). The approximate incidence of this syndrome is 1 per 1000000 births. Patients are present with typical clinical features such as intrauterine growth retardation, facial dysmorphism, severe metabolic disturbances, hepatomegaly and hypertrophic cardiomyopathy. Most DS patients die within the first two years of life due to respiratory infections, severe hypoglycemia or progressive cardiomyopathy. Treatment options are limited and no specific therapy exist for DS. Given the similarities between insulin and insulin-like growth factor 1 (IGF-1) receptors, recombinant human IGF-1 (rhIGF-1) has been used to treat severe insulin resistance including DS. We report the case of a male patient with genetically confirmed Donohue syndrome, successfully treated with continuous subcutaneous IGF1 infusion via insulin pump. We observed improvement of glycemic control, liver function and cardiac hypertrophy regression following 15-month IGF1 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Endocrinology Research Centre.
- Research Centre for medical genetics.
Zitieren
APA
Melikyan, M. A., Ivannikova, T. E., Milovanova, N. V., Kolodkina, A. A., Bezlepkina, O. B., & Mokryshevа, N. G. (2022). Donohue syndrome and use of continuous subcutaneous IGF1 pump therapy. Problems of Endocrinology, 68(5), 79-86. https://doi.org/10.14341/probl13121
Vancouver
Melikyan MA, Ivannikova TE, Milovanova NV, Kolodkina AA, Bezlepkina OB, Mokryshevа NG. Donohue syndrome and use of continuous subcutaneous IGF1 pump therapy. Problems of Endocrinology. 2022;68(5):79-86. doi:10.14341/probl13121
BibTeX
@article{Melikyan2022,
author = {Melikyan, M A and Ivannikova, T E and Milovanova, N V and Kolodkina, A A and Bezlepkina, O B and Mokryshevа, N G},
title = {Donohue syndrome and use of continuous subcutaneous IGF1 pump therapy},
journal = {Problems of Endocrinology},
year = {2022},
volume = {68},
number = {5},
pages = {79--86},
doi = {10.14341/probl13121}
}
EUVIMED